Protective effect of CV247 against cisplatin nephrotoxicity in rats. 2014

C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
Department of Pulmonology, Semmelweis University, Budapest, Hungary.

CV247 (CV), an aqueous mixture of copper (Cu) and manganese (Mn) gluconates, vitamin C and sodium salicylate increased the antitumour effects of cisplatin (CDPP; cis-diamminedichloroplatinum) in vitro. We hypothesized that the antioxidant and cyclooxygenase-2 (COX-2; prostaglandin-endoperoxide synthase 2) inhibitory components of CV can protect the kidneys from CDPP nephrotoxicity in rats. CDPP (6.5 mg/kg, intraperitoneally) slightly elevated serum creatinine (Crea) and blood urea nitrogen (BUN) 12 days after treatment. Kidney histology demonstrated extensive tubular epithelial damage and COX-2 immunoreactivity increased 14 days after treatment. A large amount of platinum (Pt) accumulated in the kidney of CDPP-treated rats. Furthermore, CDPP decreased renal iron (Fe), molybdenum (Mo), zinc (Zn), Cu and Mn concentrations and increased plasma Fe and Cu concentrations. CDPP elevated plasma free radical concentration. Treatment with CV alone for 14 days (twice 3 ml/kg/day orally) did not influence these parameters. Chronic CV administration after CDPP reduced renal histological damage and slightly decreased COX-2 immunoreactivity, while failed to prevent the increase in Crea and BUN levels. Blood free radical concentration was reduced, that is, CV improved redox homeostasis. CV restored plasma Fe and renal Fe, Mo and Zn, while decreased Pt and elevated Cu and Mn concentrations in the kidney. Besides the known synergistic antitumour effects with CDPP, CV partially protected the kidneys from CDPP nephrotoxicity probably through its antioxidant effect.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D008670 Metals Electropositive chemical elements characterized by ductility, malleability, luster, and conductance of heat and electricity. They can replace the hydrogen of an acid and form bases with hydroxyl radicals. (Grant & Hackh's Chemical Dictionary, 5th ed) Metal
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D001806 Blood Urea Nitrogen The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984) BUN,Nitrogen, Blood Urea,Urea Nitrogen, Blood
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005942 Gluconates Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters. Copper Gluconate,Gluconate, Copper

Related Publications

C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
December 2019, Journal of advanced veterinary and animal research,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
July 2008, Pakistan journal of pharmaceutical sciences,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
April 1989, Antimicrobial agents and chemotherapy,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
April 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
January 2013, Indian journal of pharmacology,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
July 2016, Canadian journal of physiology and pharmacology,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
June 2017, BMC nephrology,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
June 2002, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
January 2016, Avicenna journal of phytomedicine,
C Máthé, and G Szénási, and A Sebestény, and A Blázovics, and K Szentmihályi, and P Hamar, and M Albert
March 1996, Renal failure,
Copied contents to your clipboard!